Stock Market & Financial Investment News

News Breaks March 20, 2013 09:13 EDT PCYC Pharmacyclics price target raised to $165 from $110 at Wedbush Wedbush raised its price target to $165 for Pharmacyclics on expectations breakthrough designation in MCL will lead to an earlier than expected approval for ibrutinib. The firm also expects significant off-label use of ibrutinib across hematological malignancies and keeps an Outperform rating on shares of Pharmacyclics. News For PCYC From The Last 14 Days Check below for free stories on PCYC the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 19, 2013 17:55 EDT PCYC Pharmacyclics reports positive results from Phase 1b/2 study of Ibrutinib Subscribe for More Information 07:58 EDT PCYC Pharmacyclics data positive, says JMP Securities Subscribe for More Information June 16, 2013 13:37 EDT PCYC Pharmacyclics updates results of two Phase ll Ibrutinib studies Subscribe for More Information June 11, 2013 07:38 EDT PCYC Pharmacyclics shares should be bought, says RBC Capital Subscribe for More Information June 10, 2013 07:40 EDT PCYC Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information June 6, 2013 08:27 EDT PCYC Bernstein's biotech analysts hold an analyst/industry conference call Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.